Moderna shares surge ahead of Nasdaq‑100 inclusion and new COO appointment
Moderna (MRNA) stock jumped about 7% to $203.21 on Oct. 6, closing near its 52‑week high as the company prepared to join the Nasdaq‑100 on Oct. 9. The rally was accompanied by Citi’s downgrade of the stock to Sell with an $80 price target, citing an over‑inflated cancer pipeline outlook. Moderna also announced the return of Juan Andres to lead a newly created chief operating officer position, while its chief technology and quality officer announced retirement.
Why it matters
The index addition will trigger mandatory buying by funds that track the Nasdaq‑100, creating mechanical demand for the shares. Citi’s downgrade signals that the recent price rise may be unsustainable, warning investors that the stock could face downside pressure if expectations for the cancer program are not met.
Key facts
- 1Moderna closed at $203.21 on Oct. 6, up 6.95% from the prior session. digitaltoday.co.kr
- 2The share price rose as high as $205.77, 2.72% below the 52‑week high of $208.90. digitaltoday.co.kr
- 3Moderna will be added to the Nasdaq‑100 before the market opens on Oct. 9. digitaltoday.co.kr
- 4Citi cut its rating to Sell and raised its target price to $80 from $60 on Sept. 30. digitaltoday.co.kr
- 5Juan Andres re‑joined Moderna on Oct. 5 to head a newly created chief operating officer role. digitaltoday.co.kr
- 6Chief Technology and Quality Officer Jerh Collins announced his retirement. digitaltoday.co.kr
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.